Biopharmaceutical company HIPRA has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for the updated version of BIMERVAX®, its recombinant protein COVID-19 vaccine adapted to the XFG.1.1 variant.

This is the third adaptation of the vaccine developed by HIPRA and follows the recommendation of the EMA Emergency Task Force (EMA-ETF), which identified the XFG variant as the preferred strain for the 2026/2027 vaccination campaign based on the epidemiological situation and the available scientific evidence.

As with the previous variant-adapted version, the vaccine will be indicated for active immunisation in individuals aged 12 years and older.

Two administration formats

Following the European Commission's marketing authorisation, the COVID-19 vaccine adapted to XFG.1.1 will be available in two ready-to-use presentations: the already marketed single-dose vial and, as a new addition, a pre-filled syringe (PFS).

The introduction of this new presentation expands the options available to healthcare professionals and facilitates vaccine administration across different healthcare settings.